124 related articles for article (PubMed ID: 28322244)
21. Novel targeted agents in the treatment of multiple myeloma.
Varga C; Laubach J; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Hematol Oncol Clin North Am; 2014 Oct; 28(5):903-25. PubMed ID: 25212889
[TBL] [Abstract][Full Text] [Related]
22. Targeted Therapy in Biliary Tract Cancers.
Merla A; Liu KG; Rajdev L
Curr Treat Options Oncol; 2015 Oct; 16(10):48. PubMed ID: 26266637
[TBL] [Abstract][Full Text] [Related]
23. Current treatment strategies in Hodgkin lymphomas.
Copeland A; Younes A
Curr Opin Oncol; 2012 Sep; 24(5):466-74. PubMed ID: 22871744
[TBL] [Abstract][Full Text] [Related]
24. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
25. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Knopf KB; Duh MS; Lafeuille MH; Gravel J; Lefebvre P; Niculescu L; Ba-Mancini A; Ma E; Shi H; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):380-8. PubMed ID: 25023616
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions.
Banerjee S; Cunningham D
Clin Colorectal Cancer; 2010 Jun; 9 Suppl 1():S28-35. PubMed ID: 20630848
[TBL] [Abstract][Full Text] [Related]
27. [Carcinoma of the anal canal: state of art, issues in geriatric oncology and molecular targeted therapies].
Hau Desbat NH; Auberdiac P; Chargari C; Merrouche Y; Deutsch E; Schmitt T; de Laroche G; Magné N
Bull Cancer; 2011 Feb; 98(2):146-53. PubMed ID: 21382795
[TBL] [Abstract][Full Text] [Related]
28. Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Goldberg R
Clin Adv Hematol Oncol; 2016 Jan; 14(1):30-3. PubMed ID: 27057664
[No Abstract] [Full Text] [Related]
29. Optimum chemotherapy for the management of advanced biliary tract cancer.
Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
[TBL] [Abstract][Full Text] [Related]
30. [Targeted based therapies in metastatic breast cancer: future evolution].
Belmondo L; Montana M; Curti C; Crozet M; Rathelot P; Penot-Ragon C; Vanelle P
Therapie; 2012; 67(6):491-503. PubMed ID: 23249575
[TBL] [Abstract][Full Text] [Related]
31. Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene.
Mudry P; Slaby O; Neradil J; Soukalova J; Melicharkova K; Rohleder O; Jezova M; Seehofnerova A; Michu E; Veselska R; Sterba J
BMC Cancer; 2017 Feb; 17(1):119. PubMed ID: 28183292
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy is getting 'smarter'.
Mehrling T
Future Oncol; 2015; 11(4):549-52. PubMed ID: 25686110
[No Abstract] [Full Text] [Related]
33. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
Khan N; Moskowitz AJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy for triple-negative breast cancer: where are we?
Duffy MJ; McGowan PM; Crown J
Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
[TBL] [Abstract][Full Text] [Related]
35. Systemic therapy in the management of metastatic or advanced salivary gland cancers.
Lagha A; Chraiet N; Ayadi M; Krimi S; Allani B; Rifi H; Raies H; Mezlini A
Oral Oncol; 2012 Oct; 48(10):948-957. PubMed ID: 22698431
[TBL] [Abstract][Full Text] [Related]
36. Combining targeted drugs to stop resistant tumors.
Kaiser J
Science; 2011 Mar; 331(6024):1542-5. PubMed ID: 21436437
[No Abstract] [Full Text] [Related]
37. Adjuvant Therapy Trials.
Ursem C; Van Loon K; Venook A
Cancer J; 2016; 22(3):196-8. PubMed ID: 27341598
[TBL] [Abstract][Full Text] [Related]
38. Recent treatment advances in Hodgkin lymphoma: a concise review.
Arulogun S; Hertzberg M; Gandhi MK
Intern Med J; 2016 Dec; 46(12):1364-1369. PubMed ID: 26929077
[TBL] [Abstract][Full Text] [Related]
39. Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma.
Kahen E; Yu D; Harrison DJ; Clark J; Hingorani P; Cubitt CL; Reed DR
Cancer Chemother Pharmacol; 2016 Aug; 78(2):313-23. PubMed ID: 27324022
[TBL] [Abstract][Full Text] [Related]
40. Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?
Park JH; Tallman MS
Expert Rev Hematol; 2011 Aug; 4(4):427-36. PubMed ID: 21801134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
